US$ 24.11
fda tirzepatide shortage update Lilly's weight-loss drug removed from FDA's list Lilly's Tirzepatide No Longer on
Description
Tirzepatide activates the two hormone receptors we mentioned earlier: GLP-1 and GIP

Find the latest discounts and savings offers to lower your out-of-pocket costs

LOCATION \\ N79 W14756 Appleton Avenue | Suite 200

Do not read the syringe at an angle

What the label actually says The Mounjaro and Zepbound prescribing information states: "Available data with tirzepatide use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes." The label then references animal studies: "Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy." And the recommendation: "Advise pregnant women of the potential risk to a fetus
They may offer alternatives for acetazolamide and topiramate due to potential side effects
